149 related articles for article (PubMed ID: 28659392)
1. Change in vision-related quality of life and influencing factors in Asians receiving treatment for neovascular age-related macular degeneration.
Fenwick EK; Cheung GCM; Gan AT; Tan G; Lee SY; Wong D; Yeo I; Mathur R; Wong TY; Lamoureux EL
Br J Ophthalmol; 2018 Mar; 102(3):377-382. PubMed ID: 28659392
[TBL] [Abstract][Full Text] [Related]
2. The impact of anti-vascular endothelial growth factor treatment on quality of life in neovascular age-related macular degeneration.
Finger RP; Guymer RH; Gillies MC; Keeffe JE
Ophthalmology; 2014 Jun; 121(6):1246-51. PubMed ID: 24518613
[TBL] [Abstract][Full Text] [Related]
3. Vision-related quality of life: 12-month aflibercept treatment in patients with treatment-resistant neovascular age-related macular degeneration.
Zhu M; Wijeyakumar W; Syed AR; Joachim N; Hong T; Broadhead GK; Li H; Luo K; Chang A
Graefes Arch Clin Exp Ophthalmol; 2017 Mar; 255(3):475-484. PubMed ID: 27572301
[TBL] [Abstract][Full Text] [Related]
4. Patients' preferences in treatment for neovascular age-related macular degeneration in clinical routine.
Finger RP; Hoffmann AE; Fenwick EK; Wolf A; Kampik A; Kernt M; Neubauer AS; Hirneiss C
Br J Ophthalmol; 2012 Jul; 96(7):997-1002. PubMed ID: 22535331
[TBL] [Abstract][Full Text] [Related]
5. Treat-and-extend bevacizumab for neovascular age-related macular degeneration: the importance of baseline characteristics.
Rush RB; Simunovic MP; Vandiver L; Aragon AV; Ysasaga JE
Retina; 2014 May; 34(5):846-52. PubMed ID: 24240560
[TBL] [Abstract][Full Text] [Related]
6. Treatment patterns, visual acuity and quality-of-life outcomes of the WAVE study - a noninterventional study of ranibizumab treatment for neovascular age-related macular degeneration in Germany.
Finger RP; Wiedemann P; Blumhagen F; Pohl K; Holz FG
Acta Ophthalmol; 2013 Sep; 91(6):540-6. PubMed ID: 23171290
[TBL] [Abstract][Full Text] [Related]
7. The impact of typical neovascular age-related macular degeneration and polypoidal choroidal vasculopathy on vision-related quality of life in Asian patients.
Fenwick EK; Cheung CMG; Ong PG; Tan G; Lee SY; Yeo I; Cheng CY; Wong TY; Lamoureux EL
Br J Ophthalmol; 2017 May; 101(5):591-596. PubMed ID: 27485722
[TBL] [Abstract][Full Text] [Related]
8. Real-world 10-year experiences with intravitreal treatment with ranibizumab and aflibercept for neovascular age-related macular degeneration.
Brynskov T; Munch IC; Larsen TM; Erngaard L; Sørensen TL
Acta Ophthalmol; 2020 Mar; 98(2):132-138. PubMed ID: 31282617
[TBL] [Abstract][Full Text] [Related]
9. Significant improvements in near vision, reading speed, central visual field and related quality of life after ranibizumab treatment of wet age-related macular degeneration.
Frennesson C; Nilsson UL; Peebo BB; Nilsson SE
Acta Ophthalmol; 2010 Jun; 88(4):420-5. PubMed ID: 19678811
[TBL] [Abstract][Full Text] [Related]
10. Correlation of 3-Dimensionally Quantified Intraretinal and Subretinal Fluid With Visual Acuity in Neovascular Age-Related Macular Degeneration.
Waldstein SM; Philip AM; Leitner R; Simader C; Langs G; Gerendas BS; Schmidt-Erfurth U
JAMA Ophthalmol; 2016 Feb; 134(2):182-90. PubMed ID: 26661463
[TBL] [Abstract][Full Text] [Related]
11. Using Uniocular Visual Acuity Substantially Underestimates the Impact of Visual Impairment on Quality of Life Compared with Binocular Visual Acuity.
Kidd Man RE; Liang Gan AT; Fenwick EK; Thakur S; Gupta P; Teo ZL; Cheng CY; Wong TY; Lamoureux EL
Ophthalmology; 2020 Sep; 127(9):1145-1151. PubMed ID: 32222400
[TBL] [Abstract][Full Text] [Related]
12. ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Outcomes in Eyes With Poor Initial Vision.
Toth LA; Stevenson M; Chakravarthy U
Retina; 2015 Oct; 35(10):1957-63. PubMed ID: 25946692
[TBL] [Abstract][Full Text] [Related]
13. Visual Acuity Outcomes after Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration: Age-Related Eye Disease Study 2 Report Number 19.
Keenan TD; Vitale S; Agrón E; Domalpally A; Antoszyk AN; Elman MJ; Clemons TE; Chew EY;
Ophthalmol Retina; 2020 Jan; 4(1):3-12. PubMed ID: 31395505
[TBL] [Abstract][Full Text] [Related]
14. The Differential Impact of Age on Vision-Related Quality of Life across the Visual Impairment Spectrum.
Man REK; Gan ATL; Fenwick EK; Gupta P; Thakur S; Fang XL; Cheng CY; Wong TY; Lamoureux EL
Ophthalmology; 2021 Mar; 128(3):354-363. PubMed ID: 32738259
[TBL] [Abstract][Full Text] [Related]
15. Vision-related quality of life in Japanese patients with wet age-related macular degeneration treated with intravitreal aflibercept in a real-world setting.
Gomi F; Migita H; Sakaguchi T; Okada H; Sugawara T; Hikichi Y;
Jpn J Ophthalmol; 2019 Nov; 63(6):437-447. PubMed ID: 31673841
[TBL] [Abstract][Full Text] [Related]
16. Patterns of Early and Delayed Visual Response to Ranibizumab Treatment for Neovascular Age-Related Macular Degeneration.
Stoller GL; Kokame GT; Dreyer RF; Shapiro H; Tuomi LL
JAMA Ophthalmol; 2016 May; 134(5):545-553. PubMed ID: 27010625
[TBL] [Abstract][Full Text] [Related]
17. Macular Atrophy in Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial Comparing Ranibizumab and Aflibercept (RIVAL Study).
Gillies MC; Hunyor AP; Arnold JJ; Guymer RH; Wolf S; Pecheur FL; Munk MR; McAllister IL
Ophthalmology; 2020 Feb; 127(2):198-210. PubMed ID: 31619357
[TBL] [Abstract][Full Text] [Related]
18. Effect of Ranibizumab and Aflibercept on Best-Corrected Visual Acuity in Treat-and-Extend for Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial.
Gillies MC; Hunyor AP; Arnold JJ; Guymer RH; Wolf S; Ng P; Pecheur FL; McAllister IL
JAMA Ophthalmol; 2019 Apr; 137(4):372-379. PubMed ID: 30676617
[TBL] [Abstract][Full Text] [Related]
19. Vision-Related Quality of Life in Patients with Diabetic Macular Edema Treated with Intravitreal Aflibercept: The AQUA Study.
Garweg JG; Stefanickova J; Hoyng C; Schmelter T; Niesen T; Sowade O; Sivaprasad S;
Ophthalmol Retina; 2019 Jul; 3(7):567-575. PubMed ID: 31080168
[TBL] [Abstract][Full Text] [Related]
20. Morphologic parameters relevant for visual outcome during anti-angiogenic therapy of neovascular age-related macular degeneration.
Simader C; Ritter M; Bolz M; Deák GG; Mayr-Sponer U; Golbaz I; Kundi M; Schmidt-Erfurth UM
Ophthalmology; 2014 Jun; 121(6):1237-45. PubMed ID: 24684838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
